Association of MMP-2 (-1306 C>T), MMP-9 (-1562 C>T) Gene Polymorphism and the Formation of the Hematological Malignancies
,
Abstract
No Abstract
Wu Z, Jiang P, Zulqarnain H, Gao H, Zhang W (2015). Relationship between single-nucleotide polymorphism of matrix met-alloproteinase-2 gene and colorectal can-cer and gastric cancer susceptibility: a me-ta-analysis. Onco Targets Ther, 8:861-869.
Zhang B, Wu K, Cao Z, et al. (2004). IL-18 in¬creases invasiveness of HL-60 myeloid leuke¬mia cells: up-regulation of matrix metallopro¬teinases-9 (MMP-9) expres-sion. Leukemia Res, 28:91-95.
Zhang FL, Mi YY, Cao Q, et al. (2012). Up-date analysis of studies on the MMP-9 -1562 C>T polymorphism and cancer risk. Mol Biol Rep, 39:3435-3441.
Chaudhary AK, Pandya S, Ghosh K, Nad-karni A (2013). Matrix metalloproteinase and its drug targets therapy in solid and hematological ma¬lignancies: An overview. Mutation Res, 753:7-23.
Scrideli CA, Cortez MAA, Yunes JA, et al. (2010). mRNA expression of matrix met-alloprotein¬ases (MMPs)2 and 9 and tissue inhibitor of metalloproteinases (TIMPs)1 and 2 in child¬hood acute lymphoblastic leukemia: Potential role of TIMP1 as an adverse prognostic factor. Leukemia Res, 34:32-37.
Suminoe A, Matsuzaki A, Hattori H, Koga Y, Ishii E, Hara T (2007). Expression of matrix metal¬loproteinase (MMP) and tis-sue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leu-kemia with organ involve¬ment. Leukemia Res, 31:1437-1440.
Hazar B, Polat G, Seyrek E, Bağdatoğlu O, Kanik A, Tiftik N (2004). Prognostic val-ue of matrix metalloproteinases (MMP-2 and MMP-9) in hodgkin’s and non-hodgkin’s lymphoma. Int J Clin Pract, 58:139-143.
| Files | ||
| Issue | Vol 45 No 3 (2016) | |
| Section | Letter to the Editor | |
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
